Disease Modifying Drugs in Cystic Fibrosis
These meetings are intended for UK Healthcare Professionals and have been developed in accordance with the ABPI Code of Practice.
PM Healthcare events are Quality Assured by the University of Bradford
| Satellite | Disease Modifying Drugs in Cystic Fibrosis | |||
| Speakers | Patrick Wilson, Assistant Head of Pharmacy: Clinical and Operational Services, Nottingham University Hospitals I have been Assistant Head of Pharmacy at Nottingham University Hospitals and Clinical Services Lead since August 2017. I am also a long-standing member of the UKCPA Respiratory Group steering committee and current Chair of the UK Cystic Fibrosis Pharmacists Group (UKCFPG). Before moving to lead the clinical service I worked as the NHS England and CCG funded, embedded High Cost Drugs Pharmacist at NUH. I moved to work at NUH after over 8 years working at University Hospitals Leicester as a specialist pharmacist in Respiratory Medicine and Adult Cystic Fibrosis. I am passionate about delivering a high quality pharmacy service and the importance of knowledgeable and empathic pharmacy staff supporting people with long term conditions in getting the most out of their prescribed treatments. | |||
| Satellite Description | ||||
|
During this session we will focus on the pharmacological treatment of the underlying causes of Cystic Fibrosis, those treatments targeting the CFTR receptor and modifying its function. We will examine the currently available and pipeline products in terms of their pharmacology, evidence for their use and challenges in real-life management using these medicines. We will also cover the commissioning controversies and how people with Cystic Fibrosis access these treatments across the UK. We will then look at the resources currently available, and ongoing research into how we can best support people with Cystic Fibrosis in using these life-changing treatments safely and effectively. Advanced level. | ||||
